Cystic Fibrosis organisations in Australia provide support and services to people with Cystic Fibrosis (CF) and their carers and families. This is complemented by a commitment to research and a quality improvement program focussing on improved clinical care for people with CF.
Every four days a baby is born in Australia with cystic fibrosis (CF) and more than one million Australians are carriers of cystic fibrosis. Cystic Fibrosis Australia (CFA) is committed to improving clinical practice and patient outcomes through its quality improvement programmes and research with the aim of extending life expectancy from 37 to 50 years by 2025.
Cystic Fibrosis is a recessive genetic condition. It primarily affects the lungs and digestive system because of a malfunction in the exocrine system, responsible for producing saliva, sweat, tears and mucus.
In addition to working for a cure, Cystic Fibrosis Australia also provides support and advocacy to improve the lives of people with cystic fibrosis. Get involved by raising awareness about CF, participating in a fundraising event or volunteering.
Cystic Fibrosis Australia has established a consistent approach to advocacy across Australia and is now a subject matter expert for government, industry and the media.
The Australian Cystic Fibrosis Research Trust (ACFRT) is managed by Cystic Fibrosis Australia (CFA). Since 1989 it has funded more than 300 projects valued at over $6,000,000.
Visit the media room to browse through number of resources including media representatives, press releases and reports.
Clinical trials are listed below.
Restore CFTR FunctionCompleted with results Location: Multiple US sites
Phase 2 study of VX-152 combination drug in people with cystic fibrosis. , protocol number Vertex VX-152-102
This study is taking place at multiple care centres accross the US. It will look at the safety and tolerability of the drug VX-152 in combination with both ivacaftor and tezacaftor (VX-661).
Age:
18 years and older
Mutation(s):
homozygous or hetrozygous F508del
FEV1% Predicted:
40 - 90%
Number of Visits:
10
Length of Participation:
16 weeks
Restore CFTR FunctionEnrolling Location: Multiple care centres across the US
Phase 1/2 Study of PTI-801 drug in healthy adults and then in adults with cystic fibrosis. , protocol number Proteostasis Therapeutics NCT03140527 PTI-801-01
This study is taking place at multiple care centres across the US. It will look at the safety and tolerability of the drug PTI-801
18 years and over
No mutation requirement
8
30
Phase 3 study of tezacaftor (VX-661) combination drug in children with cystic fibrosis. , protocol number NCT02953314 VERTEX VX15-661-113
This study evaluated the safety and tolerability of the drug Tezacaftor (VX-661) in combination with ivacaftor (Kalydeco®) in children with CF. This study was for children who have two copies of the F508 del mutation or one copy of F508del and a second mutation that is either residual function or results in a gating defect and responds to ivacaftor.
6-11 years
40% or greater
9
28 weeks
ObservationalEnrolling Location: Australia, Melbourne
Multi Breath Nitrogen Washout (MBNW) as a Measure of Small Airway Function in Patients With Respiratory Disease , protocol number NCT00163696
Measurements of Inhomogeneity of the Small Airway With Patients With Cystic Fibrosis, Asthma and Bronchiolitis Obliterans Syndrome (Post Transplant) Using the Multi Breath Nitrogen Washout Technique
18-65 years
Not specified
Not Specified
OtherActive, not recruiting Location: USA
Viral pathogenisis of early cystic fibrosis lung disease , protocol number NCT01973192 1R01HL116211-01
Study will test the hypothesis that early viral infections alter the bacterial flora and inflammatory profile in the airway and accelerate progression of pulmonary disease in infants with cystic fibrosis.
2-4 months
Hetrozygous
Anti-InfectiveEnrolling Location: USA
STOP 2: Treatment of pulmonary exacerbations in people with CF , protocol number STOP2-IP-15 NCT02781610
This study is taking place at multiple care centers across the U.S. It will look at the safety and effectivness of different lengths of IV treatment for pulmonary exacerbations in people with CF.
18 Years and Older
No Mutation Requirement
25 to 100%
3
35 days
Restore CFTR FunctionCompleted with results Location: Multiple care centres across the US (healthy volunteers) & Belfast (CF)
Phase 2 Study of PTI-808 and triple combination therapy in adults with cystic fibrosis , protocol number NCT03500263 PTI-808-01 Proteostasis
This study evaluated the effectiveness and safety of the drug, PTI-808 in combination with PTI-801, with or without PTI-428. This study was for people with CF ages 18 and older who have at least one copy of the F508del CFTR mutation.
Two copies of F508del or One Copy F508del
40-90%
56 days
Restore CFTR FunctionCompleted with results Location: USA
Phase 1 exploratory study on the effect of the drug QR-010 on nasal cells. , protocol number NCT02564354 ProQR PQ-010-002
This study evaluated the effectiveness of the drug eluforsen (when sprayed in the nose) to improve nasal cell chloride transport. This study was for people with CF who have at least one copy of the F508del CFTR mutation.
Two copies F508del or One Copy F508del
7 weeks
SN06: Phase 2 study of N91115 in adults with CF who are currently taking lumacaftor/ivacaftor. , protocol number NCT02589236 NIVALIS N91115-2CF1-05
This study evaluated the safety and effectiveness of the CFTR modulator drug N91115 (cavosonstat). This study was for adults with cystic fibrosis who have two copies of F508del CFTR mutation and were also taking lumacaftor/ivacaftor (Orkambi®).
Two copies F508del
40 to 85%
Restore CFTR FunctionEnrolling Location: USA
SN07: Phase 2 study of N91115 in adults with CF who are currently taking ivacaftor , protocol number Nivalis N91115-2CF-06
This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the oral drug N91115 and will use a placebo control.
One Copy F508del or No Copies F508del
40 to 90%
12 weeks